Feasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer | Zendy

MarkD Hurwitz | Zendy; Arti Parekh | Zendy; PaulL Nguyen | Zendy; LauraJ West | Zendy; Catherine Duarte | Zendy; PowellL Graham | Zendy; D LaRock | Zendy; Vincent Yeung | Zendy

AI Assistant Blog Pricing

Open Access

Feasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer

Author(s) -

MarkD Hurwitz,

Arti Parekh,

PaulL Nguyen,

LauraJ West,

Catherine Duarte,

PowellL Graham,

D LaRock,

Vincent Yeung

Publication year - 2016

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 1998-4138

pISSN - 0973-1482

DOI - 10.4103/0973-1482.180083

Subject(s) - medicine , brachytherapy , hazard ratio , prostate cancer , confidence interval , proportional hazards model , prostate specific antigen , urology , prostate , clinical endpoint , cohort , cancer , radiation therapy , oncology , randomized controlled trial

We sought to determine whether patients with high-volume, low-risk prostate cancer are suitable candidates for ultrasound-guided brachytherapy, monotherapy alone, without supplemental external beam radiation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog